Lung Cancer
Volume 65, Issue 2 , Pages 187-191 , August 2009

A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer

Received 27 June 2008 ,Revised 27 October 2008 ,Accepted 2 November 2008.

References 

  1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2004;54(1):8–29
  2. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet. 2005;366(9494):1385–1396
  3. von PJ, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–667
  4. Ettinger DS. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol. 2001;28(2 Suppl 4):27–29
  5. Kelly K. New chemotherapy agents for small cell lung cancer. Chest. 2000;117(4 Suppl 1):156S–162S
  6. Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, Kimura M, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group. Gan To Kagaku Ryoho. 1991;18(6):1013–1019
  7. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10(8):1225–1229
  8. Le Chevalier T, Ibrahim N, Chomy P, Riviere A, Monnier A, Magherini E, et al. A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT) (Meeting abstract). Proc Am Soc Clin Oncol. 1997;16:(abstr no 1617)
  9. DeVore RF, Blanke C, Denham C, Hainsworth J, Gralla RJ, Koletsky AJ, et al. Phase II study of Irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC) (Meeting abstract). Proc Am Soc Clin Oncol. 1998;17:(abstr no 1736)
  10. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85–91
  11. Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24(13):2038–2043
  12. Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 1994;5(3):283–285
  13. Masters GA, Declerck L, Blanke C, Sandler A, DeVore R, Miller K, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol. 2003;21(8):1550–1555
  14. van dL I, Smit EF, van Putten JW, Groen HJ, Schlosser NJ, Postmus PE, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol. 2001;12(4):557–561
  15. Agelaki S, Syrigos K, Christophylakis C, Boukovinas J, Varthalitis J, Pavlakou G, et al. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Oncology. 2004;66(3):192–196
  16. Schuette W, Nagel S, Juergens S, Bork I, Wollschlaeger B, Schaedlich S, et al. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer. 2005;7(2):133–137
  17. Rocha-Lima CM, Herndon JE, Lee ME, Atkins JN, Mauer A, Vokes E, et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol. 2007;18(2):331–337
  18. Ohyanagi F, Horiike A, Okano Y, Satoh Y, Okumura S, Ishikawa Y, et al. Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemother Pharmacol. 2008;61(3):503–508
  19. Castellano D, Ciruelos E, Garcia-Giron C, Lopez-Martin A, Gerrido P, Jimeno A, et al. Phase II trial of biweekly irinotecan plus gemcitabine combination in refractory or relapsed small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 2003;22:(abstr no 2710)
  20. Domine M, Gonzales-Larriba JL, Garcia Gomez R, Provencio M, Isla D, Terrasa S, et al. CPT-11—gemcitabine for refractory or relapsed small cell lung cancer (SCLC). A Spanish multicentric phase II study. Proc Am Soc Clin Oncol. 2003;22:(abstr no 2819)
  21. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214
  22. Cancer Therapy Evaluation Program. Common toxicity criteria. Version 2.0. DCTD, NCI, NIH, DHHS; 1998.
  23. Collet D. Modelling Survival Data in Medical Research. 3rd edn.. Oxford: Blackwell Scientific; 1994;
  24. O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441–5447
  25. Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res. 2008;14(6):1788–1796

PII: S0169-5002(08)00575-8

doi: 10.1016/j.lungcan.2008.11.002

Lung Cancer
Volume 65, Issue 2 , Pages 187-191 , August 2009

Article Tools

* Image Usage & Resolution